Clinical evidence and regulatory review frameworks moved again around Moderna’s seasonal mRNA flu vaccine mRNA-1010 (mFLUSIVA). FDA documents ahead of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting June 18 indicated alignment on the application’s scientific basis after an earlier refusal-to-file reversal, while still flagging evidence gaps around populations beyond a single influenza season. In parallel, separate reporting highlights that proposed U.S. oversight rules could fundamentally disrupt clinical trial grant flows—an analysis suggests nearly 5,000 clinical trials, including 1,000 cancer studies, could face termination risk under an Office of Management and Budget rule that would give political appointees final word on federal research-grant decisions. Finally, on the governance side of AI adoption, CFO and healthcare AI stakeholders emphasized that AI value depends on data quality and governance, with humans retaining review authority—an implicit message for developers seeking regulatory-ready, auditable workflows.